Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

(Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Q2 2024 Earnings Call Transcript September 24, 2024 Operator: Good morning, and welcome to the Altamira Therapeutics First ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA ...

Small-molecule drug (ACBI3) could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to ...